GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zydus Lifesciences Ltd (BOM:532321) » Definitions » Price-to-Owner-Earnings

Zydus Lifesciences (BOM:532321) Price-to-Owner-Earnings : 51.84 (As of May. 10, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Zydus Lifesciences Price-to-Owner-Earnings?

As of today (2024-05-10), Zydus Lifesciences's share price is ₹967.80. Zydus Lifesciences's Owner Earnings per Share (TTM) ended in Mar. 2023 was ₹18.67. It's Price-to-Owner-Earnings for today is 51.84.


The historical rank and industry rank for Zydus Lifesciences's Price-to-Owner-Earnings or its related term are showing as below:

BOM:532321' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 8.25   Med: 33.92   Max: 104.19
Current: 53.4

During the past 13 years, the highest Price-to-Owner-Earnings of Zydus Lifesciences was 104.19. The lowest was 8.25. And the median was 33.92.


BOM:532321's Price-to-Owner-Earnings is ranked worse than
76.13% of 419 companies
in the Drug Manufacturers industry
Industry Median: 27.85 vs BOM:532321: 53.40

As of today (2024-05-10), Zydus Lifesciences's share price is ₹967.80. Zydus Lifesciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was ₹29.39. Therefore, Zydus Lifesciences's PE Ratio for today is 32.93.

As of today (2024-05-10), Zydus Lifesciences's share price is ₹967.80. Zydus Lifesciences's EPS without NRI for the trailing twelve months (TTM) ended in was ₹32.86. Therefore, Zydus Lifesciences's PE Ratio without NRI for today is 29.45.

During the past 13 years, Zydus Lifesciences's highest PE Ratio without NRI was 45.44. The lowest was 13.55. And the median was 22.55.


Zydus Lifesciences Price-to-Owner-Earnings Historical Data

The historical data trend for Zydus Lifesciences's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zydus Lifesciences Price-to-Owner-Earnings Chart

Zydus Lifesciences Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only 104.74 26.88 23.50 8.57 26.32

Zydus Lifesciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 26.32 - - -

Competitive Comparison of Zydus Lifesciences's Price-to-Owner-Earnings

For the Drug Manufacturers - Specialty & Generic subindustry, Zydus Lifesciences's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zydus Lifesciences's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Zydus Lifesciences's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Zydus Lifesciences's Price-to-Owner-Earnings falls into.



Zydus Lifesciences Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Zydus Lifesciences's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=967.80/18.67
=51.84

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Zydus Lifesciences  (BOM:532321) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Zydus Lifesciences Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Zydus Lifesciences's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Zydus Lifesciences (BOM:532321) Business Description

Traded in Other Exchanges
Address
Scheme No. 63, Sarkhej-Gandhinagar Highway, Zydus Corporate Park, Survey No. 536, Near Vaishnodevi Circle, Khoraj (Gandhinagar), Ahmedabad, GJ, IND, 382481
Zydus Lifesciences Ltd is a specialty and generic drug manufacturing company. The product portfolio of the group includes Active Pharmaceutical Ingredients, human formulations, Health and wellness, and Animal health and veterinary products. Its product brands include Aten, Falcigo, Nucoxia, Levoday, Metscore and Arzep among others. It has two segments Pharmaceuticals and Consumer Products. It generates majority of its revenue from the Pharmaceutical segment.

Zydus Lifesciences (BOM:532321) Headlines

No Headlines